Immunization after the elective end of antineoplastic chemotherapy in children

Pediatric Blood and Cancer

Volumn 52, Issue 2, 2009, Pages 165-168

  Fioredda, Francesca ^a   Cavillo, Michaela ^a   Banov, Laura ^a   Plebani, Alessandro ^b   Timitilli, Anna ^a   Castagnola, Elio ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Residual immunity after cancer; Vaccination after chemotherapy; Vaccination strategy

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; FLUDARABINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; MERCAPTOPURINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; RUBELLA VACCINE; STEROID; TYPHUS VACCINE; VACCINE; YELLOW FEVER VACCINE; ANTINEOPLASTIC AGENT;

ACTIVE IMMUNIZATION; ANTIBODY TITER; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; INFECTION; INFECTION RISK; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; IMMUNIZATION; OPPORTUNISTIC INFECTION;

ANTINEOPLASTIC AGENTS; CHILD; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNIZATION; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES AS TOPIC;

EID: 59449107319     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21864     Document Type: Review

References (43)

1. Crawford NW, Heath JA, Buttery JP. Immunisation practice of paediatric oncologists: An Australasian survey. J Paediatr Child Health 2007;43:593-596.
2. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. Stem Cells 2000;18:10-18.
3. Adamson PC, Balis FM, Berg S, et al. General principles of chemotherapy from Pizzo DA and Poplack DG Principles and practice of pediatric oncology, 5th edition. 2006. pp. 290-365.
4. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukaemia. Cancer 1992;69:1481-1486.
5. Mackall CL, Fleischer TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228.
6. Alanko S, Pelliniemi TT, Salmi TT. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukaemia and solid tumors. Med Pediatr Oncol 1995;24:373-378.
7. Haining WN, Neuberg DS, Keczkemethy HL et al. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukaemia. Blood 2005;5:1749-1754.
8. Ek T, Mellander L, Andersson B, et al. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005;44:461-468.
9. Mustafa MM, Buchanan GR, Winick NJ. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol 1998;20:451-457.
10. Smith SJ, Schiffman G, Karayalcin G, et al. Immunodeficiency in long term survivors of acute lymphoblastic leukaemia treated with Berlin-Frankfurt- Munster therapy. J Pediatr 1995;1:68-75.
11. de Vaan GA, van Munster PJ, Bakkeren JA. Recovery of immune function after cessation of maintenance therapy in acute lymphoblastic leukemia (ALL) of childhood. Eur J Pediatr 1982;139:113-117.
12. Galazka AM. The immunological basis for immunization WHO GENEVA. In: Expanded program on immunization. Geneva: World Health Organization; 1993. p 5-14. Available on line at http://whlibdoc.who.int/hq/1995/WHO-EPI-GEN-95.03- REV.1.pdf
13. Bartolozzi G. Difterite. In: Bartolozzi G, editor. Vaccini e Vaccinazioni. Milano, Italy: Masson; 2005. pp. 267-295.
14. Ek T, Mellander L, Hanh-Zoric M, et al. Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia implications for vaccination strategies. Acta Paediatr 2006;95:701-706.
15. Brodtman DH, David WR, Redner A, et al. Immunodeficiency in children with acute lymphoblastic leukaemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005;146:654-661.
16. Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002;109:e9.
17. Reinhardt D, Houliara K, Pekrun A, et al. Impact of conventional chemotherapy on levels of antibodies against vaccine preventable diseases in children treated for cancer. Scand J Infect Dis 2003;35:851-857.
18. Feldman S, Andrew M, Norris M, et al. Decline in rates of seropositivity for measles, mumps and rubella antibodies among previously immunized children treated for acute leukaemia. Clin Infect Dis 1998;27:388-390.
19. Ercan TE, Soycan LY, Apak H, et al. Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2005;27:273-277.
20. Fioredda F, Plebani A, Hanau G, et al. Re-immunisation schedule in leukaemic children after intensive chemotherapy: A possible strategy. Eur J Haematol 2005;74:20-23.
21. Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 2004;101:635-641.
22. Patel SR, Ortin M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007;44:635-642.
23. von der Hardt K, Jungert J, Beck JD, et al. Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents a retrospective analysis. Vaccine 2000;18:2999-3004.
24. Kantar M, Centigul N, Kansoy S, et al. Immune deficiencies following cancer treatment in children. J Trop Pediatr 2003;49:286-290.
25. van der Does A, Hermans J, Nagel J, et al. Immunity to diphtheria, pertussis, tetanus and poliomyelitis in children with acute lymphocytic leukaemia after cessation of chemotherapy. Pediatrics 1981;67:222-229.
26. Yu J, Chou AJ, Lennox A, et al. Loss of antibody titers and effectiveness of revaccination in post-chemotherapy pediatric sarcoma patients. Pediatr Blood Cancer 2007;49:656-660.
27. Voic SM, Almeida MTA, Cornacchion AL, et al. Measles and rubella antibody status in children after treatment for acute lymphoblastic leukaemia. J Pediatr (Rio J) 2006;82:481-484.
28. Marc-Berard P, Floret D, Schell M, et al. Immunization for children treated for solid tumours: What are the guidelines? Arch Pediatr 2001;8:734-743.
29. Van Tilburg CM, Sanders EAM, Rovers MM, et al. Loss of antibodies and response to re-vaccination in children after treatment for acute lymphocytic leukemia: A systematic review. Leukemia 2006;20:1717-1722.
30. Royal College of Paediatrics and Child Health Immunisation of the immunocompromised child. Best Practice Statement London: RCPCH, 2002. www.rcpch.ac.UK.
31. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins in Persons with Altered Immunocompetence. MMWR 1993;42: (NoRR-4).
32. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on immunization. MMWR 2006;55: (NoRR-15).
33. CDC Recommendations of the Advisory Committee on Immunization Practices (ACIP): Recommended adult immunization schedule . MMWR 2005;54: (No 40).
34. Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: A brief review of current recommendations for practical purpose. Eur J Haematol 2003;71:319-326.
35. Price VE, Blanchette VS. Ford-JonesEL The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am 2007;21:697-710.
36. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996;173:256-258.
37. Yue Y, Kaur A, Eberhardt MK, et al. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 2007;81:1095-1099.
38. Hamarstom V, Pauksen K, Oberg G, et al. Tetanus immunity in patients with hematological malignancies. Support Care Cancer 1998;6:469-472.
39. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: A13-year experience at a single Italian institution. Eur J Cancer 2005;41:1439-1445.
40. Haupt R, Romanengo M, Fears T, et al. Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: A 12-year experience at a single Italian institution. Eur J Cancer 2001;37:2413-2419.
41. Werba BE, Hobbie W, Kazak A, et al. Classifying the intensity of pediatric cancer treatment protocols: The intensity of treatment rating scale 2.0 (ITR-2). Pediatr Blood Cancer 2007;48:673-677.
42. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or receiving hemopoietic stem cell transplant. Clin Infect Dis 2007;45:1296-1304.
43. Castagnola E, Conte M, Parodi S, et al. Incidence of bacteremias and invasive mycoses in children with high risk neuroblastoma. Pediatr Blood Cancer 2007;49:672-677.